A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients
Trending
- Future Directions and Key Takeaways in the Field of cSCC
- Many cancer survivors have impairments that make using mobile devices and websites difficult
- Clinical Scenarios: Matching Regimen to Patient Profile
- Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls
- Debunking the biggest myths about sun safety – Cancer Research UK
- Boy, 13 one of Scotland’s first to undergo innovative brain surgery
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression
Monday, July 20
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients
By NewsCancer
